UAE Oncology & Cancer Treatment Center: DHA/DOH Facility License Guide 2026

Updated August 2026.

Cancer remains among the top five causes of mortality in the UAE according to MoHAP National Cancer Registry 2024, with colorectal, breast, and thyroid cancers representing the most frequently diagnosed malignancies. The UAE Cancer Strategy 2031 targets a 20% reduction in cancer mortality through earlier detection and access to evidence-based treatment, creating both a public health imperative and a significant commercial opportunity for private oncology centres.

Establishing an oncology and cancer treatment centre in the UAE is one of the most capital-intensive and regulatory-complex healthcare ventures in the region. This guide provides a comprehensive roadmap of the DHA, DOH, MOHAP, and FANR requirements necessary to open, staff, equip, and operate a compliant cancer treatment facility.

DHA Oncology Facility License: Categories and Requirements

The Dubai Health Authority classifies oncology facilities under three primary categories, each with escalating regulatory requirements:

• Category 1 — Medical Oncology Day Unit: Outpatient chemotherapy and targeted therapy infusion. Requires a DHA-licensed Medical Oncologist, a DHA-licensed oncology-trained nurse (minimum 2 per infusion chair), a clean-room pharmacy for chemotherapy preparation, and negative-pressure infusion bays for cytotoxic agent safety.
• Category 2 — Comprehensive Outpatient Cancer Centre: Includes medical oncology, haematology oncology, radiation oncology (if linear accelerator is present), and surgical oncology consultation. Requires all relevant specialist DHA registrations and a multidisciplinary tumour board operating weekly.
• Category 3 — Inpatient Cancer Hospital: Full inpatient oncology admissions including stem cell transplant units (HSCT). Requires DHA Hospital Licence and compliance with the DHA Inpatient Oncology Standards (IOS-2023), including HEPA-filtered HSCT rooms and 24/7 haematology on-call.

DHA facility license for a Category 1 Day Unit: AED 35,000–50,000 annually. Category 2 Comprehensive Centre: AED 80,000–150,000 annually. DHA requires that chemotherapy compounding is performed only by DHA-licensed pharmacists in a laminar flow clean room certified to ISO 5 (Grade A) standards under USP 797 or equivalent.

DOH Abu Dhabi Cancer Care Facility Standard (CCF-2023)

The Department of Health Abu Dhabi issued the Cancer Care Facility Standard (CCF-2023) as the comprehensive regulatory framework for oncology services. CCF-2023 mandates:

• A Multidisciplinary Team (MDT) tumour board meeting for each new cancer diagnosis, with a minimum of six specialists participating: medical oncologist, radiation oncologist, surgical oncologist, radiologist, pathologist, and palliative care physician. MDT meeting records must be submitted to MALAFFI (Abu Dhabi Health Information Exchange) within 5 working days.
• A designated cancer nurse navigator (minimum 1 per 50 active cancer patients) responsible for care coordination across the treatment pathway.
• Participation in at least one DOH-approved clinical trial protocol or membership of an international oncology clinical research network (e.g., ASCO TAPUR, ESMO designated centre criteria).
• Psycho-oncology services either in-house or under formal referral protocol; DOH CCF-2023 cites the UAE mental health burden among cancer patients at 43% for significant anxiety or depression.

MOHAP Chemotherapy Unit and Cytotoxic Drug Regulations

MOHAP Federal Drug Agency (FDA UAE) regulates the import, compounding, and dispensing of cytotoxic chemotherapy agents. Key requirements for UAE oncology facilities:

• Controlled Drug Import Permit: Chemotherapy agents classified as psychotropic or controlled under UAE Federal Law No. 14 of 1995 require a MOHAP import permit per consignment. The attending oncologist must be listed as the responsible prescribing physician on the import documentation.
• Pharmacy Compounding Licence: On-site chemotherapy compounding requires a MOHAP Pharmacy Practice Licence specifying “Cytotoxic Compounding” as a permitted activity. The pharmacy must pass a MOHAP technical inspection confirming ISO 5 clean room conditions, biological safety cabinet (BSC Class II B2) certification, and cytotoxic spillage management protocols.
• Biological Agent Handling: Immunotherapy agents (checkpoint inhibitors: pembrolizumab, nivolumab, atezolizumab) are registered as biological medicines under MOHAP; their in-UAE importation and dispensing requires the same Pharmacy Practice Licence as cytotoxics.

FANR Radiation Therapy Licence: Linear Accelerator and PET-CT

The Federal Authority for Nuclear Regulation (FANR) is the UAE’s independent nuclear regulator and issues licences for all radiation-emitting medical devices. For oncology facilities:

• Linear Accelerator (LINAC): Radiation therapy using a LINAC (e.g., Varian TrueBeam, Elekta Synergy) requires a FANR Class II Radiation Facility Licence. Application involves submission of the LINAC shielding design (concrete bunker calculations reviewed by FANR), recruitment of a Medical Physicist (FANR-registered) and Radiation Safety Officer (RSO), and a commissioning inspection by FANR before the first patient treatment. FANR licence fee: AED 50,000–80,000 initial; AED 30,000–50,000 annual renewal per device.
• PET-CT Scanner: A PET-CT scanner (e.g., Siemens Biograph mCT, GE Discovery MI) requires FANR licence for the radioactive tracer (FDG) handling and, if an on-site cyclotron is planned, a FANR Nuclear Installation Licence — one of the most complex regulatory undertakings in UAE healthcare. Most oncology centres opt instead for an FDG supply agreement with the UAE’s operating radiopharmacy (currently IAEA-supported at Tawam Hospital, Abu Dhabi; commercial radiopharmacy at Mediclinic City Hospital DHCC).

DHCC Zone: Oncology Network and Referral Advantages

Dubai Healthcare City (DHCC) is the UAE’s preferred location for oncology centre establishment due to its existing concentration of specialist clinics and hospital proximity:

• Mediclinic City Hospital DHCC operates a full oncology programme including linear accelerator, PET-CT, and stem cell transplant services, creating cross-referral opportunities for smaller oncology centres sharing the campus.
• DHCC Phase 2 offers purpose-built oncology facility shells with pre-planned shielding wall specifications for LINAC bunker installation, reducing build-out lead time by 6–12 months.
• DHCCA oncology facility licensing allows co-location of complementary services (palliative care, integrative oncology, clinical trials coordination) under a single DHCCA facility licence, reducing administrative overhead.

Insurance Coverage: Daman, Thiqa, and International Plans

Oncology insurance reimbursement in the UAE operates through three main payer channels:

• Daman Thiqa (Abu Dhabi government employees): Covers all evidence-based oncology treatments including chemotherapy, targeted therapy, immunotherapy, and radiation therapy at DOH-licensed facilities. Reimbursement follows the Abu Dhabi Benefit Package for Oncology (ABPO), published annually by DOH. Prior authorisation via the MALAFFI system is mandatory for all systemic therapies. ABPO monthly drug cost caps for novel immunotherapies: AED 40,000–120,000/month.
• Daman Enhanced (Abu Dhabi private sector): Covers oncology up to annual limits of AED 500,000–2,000,000 depending on plan tier. Biosimilar substitution is mandated where available.
• Dubai DHA Mandatory Health Insurance (MHI) Essential Benefits: Covers inpatient chemotherapy and radiotherapy with a co-pay structure. DHA Essential Benefits do not cover outpatient targeted therapy or immunotherapy — these require enhanced plan add-ons. Major international insurers (Cigna, Bupa, Allianz) covering expatriate populations provide the highest oncology coverage levels.

Pathology, Tumour Marker Labs, and Molecular Oncology

A complete oncology centre must have robust pathology and molecular oncology testing capability. Options for UAE oncology facilities:

• In-house histopathology: Requires a DHA-licensed anatomical pathologist and a separate DHA Lab Licence. Capital cost AED 400,000–800,000 including tissue processor, staining platforms, and molecular testing equipment.
• Reference laboratory agreements: Most small to mid-size oncology centres in UAE contract pathology services to Synlab UAE, Aster Labs, or Al Jalila Hospital Pathology, with turnaround times of 3–5 business days for standard histopathology and 7–14 days for genomic profiling (e.g., Foundation One CDx, Guardant360).
• Liquid biopsy: Circulating tumour DNA (ctDNA) testing for treatment monitoring is reimbursed by Daman Thiqa for select indications; cash-pay ctDNA panels cost AED 8,000–18,000 in the UAE market (2026).

Cost Breakdown: AED 3,000,000–20,000,000+ Cancer Centre Setup

Cost Item	Medical Oncology Day Unit (AED)	Comprehensive Cancer Centre (AED)
Fit-out & Bunker/Shielding	500,000 – 1,000,000	3,000,000 – 7,000,000
LINAC / Radiation System	—	5,000,000 – 10,000,000
PET-CT Scanner	—	3,000,000 – 5,000,000
Clean Room Pharmacy Setup	300,000 – 600,000	600,000 – 1,200,000
DHA/FANR/MOHAP Licences	100,000 – 200,000	300,000 – 600,000
Specialist Staffing (12 months)	1,500,000 – 3,000,000	5,000,000 – 10,000,000
Total Estimated Range	2,400,000 – 4,800,000	16,900,000 – 33,800,000

Frequently Asked Questions

Does a UAE oncology centre need a FANR licence for chemotherapy?

No. FANR regulates ionising radiation sources; chemotherapy agents are cytotoxic drugs regulated by MOHAP, not FANR. A FANR licence is required for radiation therapy equipment (LINAC, brachytherapy), PET-CT radiotracer handling, and any other radioisotope use. Chemotherapy-only facilities (medical oncology day units) require a MOHAP Pharmacy Compounding Licence for the clean-room pharmacy, and a DHA oncology facility licence, but no FANR involvement.

What is the minimum number of infusion chairs required for a UAE oncology day unit?

DHA does not specify a minimum number of infusion chairs in its Medical Oncology Day Unit standard. However, practical commercial viability typically requires a minimum of 6 infusion chairs (each with a minimum 3 sqm treatment space, reclining chair, IV pole, monitoring equipment access, and nurse call system). Dubai Municipality Building Code (DMBC) and DHA infection control standards specify aisle widths and spacing between chairs in open-bay infusion areas. Private rooms for immunotherapy agents requiring extended monitoring (e.g., CAR-T therapy) require a minimum of 15 sqm per room.

Can a UAE oncology clinic conduct clinical trials?

Yes. Clinical trials in UAE oncology settings are regulated by MOHAP Research Ethics Committee (REC) and require a site-specific approval from DHA (Dubai) or DOH (Abu Dhabi) Research Affairs departments. Phase I trials additionally require MOHAP Clinical Trial Unit (CTU) review. The sponsoring pharmaceutical company must be registered in the UAE or appoint a UAE-based Contract Research Organisation (CRO) as the local regulatory agent. DHCC-based oncology centres benefit from streamlined DHCCA Research Governance support.

What are the DHA requirements for a bone marrow transplant (HSCT) unit?

A haematopoietic stem cell transplant (HSCT) unit requires a DHA Hospital Licence (inpatient), DHA Inpatient Oncology Standards (IOS-2023) compliance including HEPA-filtered positive-pressure HSCT rooms, 24/7 haematology and infectious disease on-call coverage, a certified apheresis unit for peripheral blood stem cell collection, and a cryopreservation facility. DHA Circular 2023/HSCT-01 requires HSCT units to report outcomes to the DHA Cancer Registry and maintain JACIE (Joint Accreditation Committee ISCT-EBMT) accreditation within 3 years of opening.

How are oncology drug costs managed under UAE insurance?

Oncology drug cost management in the UAE follows a prior authorisation model. For Daman Thiqa patients, prior authorisation via the MALAFFI Health Information Exchange is mandatory before initiating any systemic cancer therapy. For DHA plans, TPAs (NAS, Nextcare) require a specialist oncologist treatment plan with evidence-based indication, staging documentation, and, for novel agents, NCCN Category 1 or 2A evidence. Step therapy (requiring failure of standard-of-care before approving novel agents) is applied by most UAE insurers for targeted therapy and immunotherapy. Oncology facilities that employ dedicated insurance pre-authorisation nurses reduce approval timelines from 7–14 days to 3–5 days.